While we can honestly say that RepliCel Life Sciences, Inc. (OTC:REPCF) has been one of the most heavily promoted stocks for the last three days, the third parties staying behind the huge advertising campaign have little reason to be satisfied with its outcome.
The first promotional email in support of REPCF arrived shortly after the end of Tuesday’s session. A dozen mails reached our database on the following morning. In the end, REPCF closed Wednesday’s trade at 2.13, up 1.43% from its pre-promo close. The investor awareness program again resumed on Wednesday evening. As a result, REPCF closed the Apr. 19 session at $2.11 losing 0.94% of its market value. A total of 91,235 shares changed hands, which is considerably higher than the daily average trading volume of 17,517.
RepliCel Life Sciences, Inc. is a biotech company focused on developing an autologous cell implantation technology aimed at providing a solution for hair loss in both men and women. While the company has so far undertaken a number of clinical trials, it has yet to offer a final product on the market. The company recently closed a private placement financing grossing in excess of $1.3 million.
As of Sept. 30, 2011, REPCF’s financial state was determined by:
- cash reserves of $1.2M;
- net working capital of approx. $1M;
- net quarterly loss of $0.9M and a nine-month cumulative net loss of $2.9M.
Even though REPCF has been incurring losses for quite a while now, the company is actively seeking to develop the ultimate solution to a problem as old as the hills. In this respect, its market value will definitely go through the roof in the event of a successful step forward, no matter how slim the odds might seem.
